Postgraduate Program in Nursing, Federal University of Pelotas, Rio Grande do Sul, Brazil; Faculty of Nursing, Federal University of Pelotas, Brazil.
Faculty of Nursing, Federal University of Pelotas, Brazil.
Clin Nutr. 2021 Jul;40(7):4595-4605. doi: 10.1016/j.clnu.2021.06.007. Epub 2021 Jun 16.
BACKGROUND & AIMS: Melatonin appears as a supplement capable of helping with diabetes. However, there is no evidence from meta-analyses that showed significant results in insulin resistance and glycated hemoglobin. This study aimed to review the literature on randomized clinical trials that evaluated melatonin supplementation effects, compared to placebo, on diabetes parameters in humans.
We conducted a systematic review and meta-analysis in the following databases: Pubmed, LILACS, Scielo, Scopus, Web of Science, Cochrane, and Embase. We included randomized clinical trials investigating melatonin supplementation's effects, compared to placebo, on fasting blood glucose, insulin resistance, and glycated hemoglobin. Non-randomized clinical trials, observation studies, and animal models were excluded. The Cochrane scale assessed the quality of the studies. We conducted a meta-analysis on fasting blood glucose, insulin resistance, and glycated hemoglobin.
Sixteen studies were included, of which 56% showed benefits from supplementation with melatonin in diabetes parameters compared with placebo. Our meta-analysis showed significant results for fasting blood glucose [mean difference: -4.65; 95% CI: -8.06, -1.23; p = < 0.01; I = 58%], glycated hemoglobin [mean difference: -0.38; 95% CI: -0.67, -0.10; p = 0.30; I = 18%], and insulin resistance [mean difference: -0.58; 95% CI: -1.00, -0.15; p = 0.17; I = 35%].
Our results showed that melatonin supplementation was useful for reducing diabetes parameters when compared to placebo.
褪黑素作为一种补充剂，似乎有助于治疗糖尿病。然而，荟萃分析尚无证据表明其在胰岛素抵抗和糖化血红蛋白方面有显著效果。本研究旨在综述评估褪黑素补充剂与安慰剂相比对人类糖尿病参数影响的随机临床试验文献。
我们在以下数据库中进行了系统评价和荟萃分析：PubMed、LILACS、SciELO、Scopus、Web of Science、Cochrane 和 Embase。我们纳入了评估褪黑素补充剂与安慰剂相比对空腹血糖、胰岛素抵抗和糖化血红蛋白影响的随机临床试验。排除非随机临床试验、观察性研究和动物模型。Cochrane 量表评估了研究的质量。我们对空腹血糖、胰岛素抵抗和糖化血红蛋白进行了荟萃分析。
纳入了 16 项研究，其中 56%的研究显示褪黑素补充剂在糖尿病参数方面优于安慰剂。我们的荟萃分析显示空腹血糖[平均差：-4.65；95%置信区间：-8.06，-1.23；p<0.01；I=58%]、糖化血红蛋白[平均差：-0.38；95%置信区间：-0.67，-0.10；p=0.30；I=18%]和胰岛素抵抗[平均差：-0.58；95%置信区间：-1.00，-0.15；p=0.17；I=35%]的结果有统计学意义。
与安慰剂相比，褪黑素补充剂在降低糖尿病参数方面可能是有用的。
